This review discusses targeted therapy and molecular mechanisms in immunoglobulin A nephropathy, highlighting implications for individualized care.
Key Points
Emerging targeted therapies improve outcomes for patients with immunoglobulin a nephropathy, addressing both immune pathways and fibrosis.
Current management strategies, including proteinuria resolution and personalized treatments, are essential in minimizing long-term renal failure risk.
The spiral hypothesis offers a dynamic understanding of immunoglobulin a nephropathy, framing the disease as a cycle of immune injury rather than a singular event.
Future research must focus on optimizing treatment protocols for high-risk patients and ensuring effective long-term safety monitoring.